<DOC>
	<DOC>NCT02791516</DOC>
	<brief_summary>A multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of 6 months treatment with Romosozumab compared to placebo by determining the percent changes in bone mineral density</brief_summary>
	<brief_title>A Safety and Efficacy Study to Evaluate AMG 785 in South Korean Women With Osteoporosis.</brief_title>
	<detailed_description>This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in women with osteoporosis. The study is designed to evaluate if treatment with Romosozumab (AMG 785) once a month for 6 months compared with placebo is effective in increasing bone mineral density.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<criteria>Ambulatory postmenopausal Korean women, ≥ 55 to ≤ 90 years of age at enrollment. Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to screening. BMD Tscore &lt;/= 2.50 at the lumbar spine, total hip or femoral neck. At least 2 vertebrae in the L1 through L4 region and at least one hip are evaluable by DXA. Other inclusion criteria may apply. Subjects with a BMD Tscore &lt;/= 4.0 at the lumbar spine, total hip, or femoral neck. History of hip fracture. Bone disease other than osteoporosis/ or evidence of any other clinically significant disorder, condition/ or disease or significant laboratory abnormalities. Known sensitivity or intolerance calcium and vitamin D products. Other exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Osteoporosis.</keyword>
	<keyword>Osteoporosis-Postmenopausal.</keyword>
	<keyword>Bone Diseases-Metabolic.</keyword>
	<keyword>Bone Diseases.</keyword>
	<keyword>Musculoskeletal Diseases.</keyword>
</DOC>